SM-102 is an ionizable cationic lipid (pKa = 6.68) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and plasmid DNA in vitro and in vivo.
 
It inhibits inward-rectifying potassium currents mediated by human-ether-a-go-go (hERG), also known as Kv11.1, in GH3 rat pituitary cells and MA-10 mouse Leydig cells (IC50s = 108 and 98 µM, respectively).
 
Administration of luciferase mRNA in SM-102-containing LNPs induces hepatic luciferase expression in mice.1 LNPs containing SM-102 and Q1-SM-102 (Item No. 41239) as a cationic lipid pair (CLP) and encapsulating a luciferase reporter induce luciferase expression in the lungs and spleen in mice.
 
Intramuscular immunization of LNPs containing SM-102 and encapsulating mRNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein increases serum SARS-CoV-2 spike glycoprotein-specific IgG titers in mice.
 
LNPs containing SM-102 and encapsulating mRNA encoding β-catenin increase bone volume in a mouse model of tibia fracture repair when administered via injection to the fracture callus.
 
Formulations containing SM-102 have been used in the development of LNPs for delivery of mRNA-based vaccines.
 
Shipping & Storage Information
Storage: -20°C
Shipping: Wet ice in continental US; may vary elsewhere
Stability: ≥ 1 year
 
 
NOTE: Research Use Only